At a recent meeting, ECOG-ACRIN leaders and members celebrated the conclusion of enrollment to the landmark NCI-MATCH clinical trial
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
The ComboMATCH registration trial opens; NCI creates Clinical Trials Innovation unit, unveils revised National Cancer Plan
ComboMATCH researchers are discovering new drug combinations that show promise for patients with advanced cancers, based on strong pre-clinical in vivo evidence of therapeutic effectiveness
Reflections on NCI-MATCH and its successor trials; research results in leukemia and breast cancer; and grant renewal preparations
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
President Biden to appoint Dr. Monica Bertagnolli as NCI Director; NCI-MATCH trial data leads to FDA drug approval
Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation